Logo image of OSTX

OS THERAPIES INC (OSTX) Stock Fundamental Analysis

NYSEARCA:OSTX - NYSE Arca - US68764Y2072 - Common Stock - Currency: USD

1.89  +0.03 (+1.61%)

After market: 1.8218 -0.07 (-3.61%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to OSTX. OSTX was compared to 571 industry peers in the Biotechnology industry. OSTX has a bad profitability rating. Also its financial health evaluation is rather negative. OSTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OSTX has reported negative net income.
OSTX Yearly Net Income VS EBIT VS OCF VS FCFOSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M

1.2 Ratios

OSTX has a Return On Assets of -375.20%. This is amonst the worse of the industry: OSTX underperforms 96.63% of its industry peers.
Industry RankSector Rank
ROA -375.2%
ROE N/A
ROIC N/A
ROA(3y)-1516.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSTX Yearly ROA, ROE, ROICOSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

OSTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSTX Yearly Profit, Operating, Gross MarginsOSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

OSTX has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, OSTX has an improved debt to assets ratio.
OSTX Yearly Shares OutstandingOSTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
OSTX Yearly Total Debt VS Total AssetsOSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 5M 10M

2.2 Solvency

OSTX has an Altman-Z score of -24.85. This is a bad value and indicates that OSTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -24.85, OSTX is not doing good in the industry: 89.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.85
ROIC/WACCN/A
WACCN/A
OSTX Yearly LT Debt VS Equity VS FCFOSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

OSTX has a Current Ratio of 0.76. This is a bad value and indicates that OSTX is not financially healthy enough and could expect problems in meeting its short term obligations.
OSTX's Current ratio of 0.76 is on the low side compared to the rest of the industry. OSTX is outperformed by 91.47% of its industry peers.
OSTX has a Quick Ratio of 0.76. This is a bad value and indicates that OSTX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.76, OSTX is not doing good in the industry: 91.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.76
OSTX Yearly Current Assets VS Current LiabilitesOSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for OSTX have decreased strongly by -40.49% in the last year.
EPS 1Y (TTM)-40.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OSTX will show a very strong growth in Earnings Per Share. The EPS will grow by 28.89% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-182.72%
EPS Next 2Y96.8%
EPS Next 3Y28.89%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OSTX Yearly Revenue VS EstimatesOSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10M 20M 30M
OSTX Yearly EPS VS EstimatesOSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSTX. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 2.62 indicates a rather cheap valuation of OSTX.
Based on the Price/Forward Earnings ratio, OSTX is valued cheaply inside the industry as 99.29% of the companies are valued more expensively.
OSTX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.62
OSTX Price Earnings VS Forward Price EarningsOSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSTX Per share dataOSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as OSTX's earnings are expected to grow with 28.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y96.8%
EPS Next 3Y28.89%

More info and screens

0

5. Dividend

5.1 Amount

OSTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OS THERAPIES INC

NYSEARCA:OSTX (2/20/2025, 8:04:03 PM)

After market: 1.8218 -0.07 (-3.61%)

1.89

+0.03 (+1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change14.47%
Ins Owners24.84%
Ins Owner Change0%
Market Cap40.14M
Analysts82.22
Price Target14.96 (691.53%)
Short Float %1.83%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.79%
PT rev (3m)-2.22%
EPS NQ rev (1m)-30.3%
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.02%
EPS NY rev (3m)6.02%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.33%
Revenue NY rev (3m)-75.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.62
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.72
Fwd EY38.14%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -375.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1516.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.76
Altman-Z -24.85
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-182.72%
EPS Next 2Y96.8%
EPS Next 3Y28.89%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.71%
OCF growth 3YN/A
OCF growth 5YN/A